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Molecular mechanisms involved in pathogenesis of malignant melanoma have been 
widely studied and novel therapeutic treatments developed in recent past years. 
Molecular targets for therapy have mostly been recognized in the RAS–RAF–MEK–ERK 
and PI3K–AKT signaling pathways; small-molecule inhibitors were drawn to specifically 
target key kinases. Unfortunately, these targeted drugs may display intrinsic or acquired 
resistance and various evidences suggest that inhibition of a single effector of the signal 
transduction cascades involved in melanoma pathogenesis may be ineffective in blocking 
the tumor growth. In this sense, a wider comprehension of the multiple molecular alter-
ations accounting for either response or resistance to treatments with targeted inhibitors 
may be helpful in assessing, which is the most effective combination of such therapies. 
In the present review, we summarize the known molecular mechanisms underlying either 
intrinsic and acquired drug resistance either alternative roads to melanoma pathogene-
sis, which may become targets for innovative anticancer approaches.
Keywords: molecular melanoma classification, melanoma pathogenesis, signal transduction cascades, targeted-
therapy resistance, alternative therapeutic targets
introduction
Melanoma is a heterogeneous disease, with complex pathogenetic mechanisms, as a consequence 
of specific genetic alterations within several functionally related molecular pathways (1). In fact, 
studies on genetic and molecular characteristics of melanoma have provided the identification of 
some specific alterations in pathways controlling cell proliferation, differentiation, and survival. 
From the practical point of view, increasing evidences indicate that some differences in biological 
and clinical behaviors within the traditional subgroups of melanomas defined by conventional 
diagnostic procedures are due to the existence of different “molecular subtypes” of the disease (2). 
Actually, the criteria commonly used to classify melanomas are based on: (a) relationship between 
the degree of sun exposition and the site of primary tumor [according to such criteria, melanomas 
are classified into four groups: melanoma on skin with or without chronic sun-damage (CSD or 
non-CSD melanoma); melanoma on palms, soles, and nail bed (acral melanoma); and melanoma 
on mucous membrane (mucosal melanoma)] (1) or (b) evaluation of the tumor growth pattern 
[according to this criterion, four histological types of melanoma have been described: superficial 
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spreading melanoma (SSM), lentigo maligna melanoma (LMM), 
nodular melanoma (NM), and acral lentiginous melanoma 
(ALM)] (3).
Despite the incidence of melanoma has been growing faster 
than other human cancers during last decades among Caucasian 
populations (4), most of melanoma cases is diagnosed at early 
stages of the disease. When patients instead present with an 
advanced disease (i.e., melanoma is not localized anymore and 
dissemination of tumor cells to loco-regional or distant sites 
occurs), very poor survival rates have been reported, due to the 
lack of effective therapies (3). This, however, happened until 
few years ago. Very recent advances in molecular oncology 
have indeed yielded new treatment strategies that target either 
key effectors of the pathways found to play a major role in the 
pathogenesis of melanoma – such as those depending on activa-
tion of BRAF, NRAS, or cKIT genes – either immune regulatory 
molecules involved in suppression of the antitumor immune 
response – such as T-lymphocyte-associated antigen 4 (CTLA4), 
programed cell death 1 (PD-1), and its ligand (PD-L1) (5).
Although inhibitors of oncogenic BRAF generally exert a 
temporary therapeutic efficacy in patients with metastatic BRAF-
mutated melanoma, recent evidences seem to indicate that subsets 
of such cases may present a long-term response to single-agent 
BRAF inhibition (6). Combination of BRAF and MEK inhibitors 
has been even proposed as a new targeted-therapy standard of 
care for BRAFV600-positive metastatic melanomas (7).
Monoclonal antibodies directed against the immune 
 checkpoints – such as CTLA-4 (ipilimumab), PD-1 (nivolumab 
and pembrolizumab), or PD-L1 (BMS936559, MPDL3280A, and 
MEDI4736) – have been demonstrated to achieve durable anti-
tumoral responses with significantly prolonged overall survivals 
in patients with metastatic melanoma (8). Despite the increased 
attention is currently paid to cancer immunotherapy (especially, 
treatments targeting PD-1/PD-L1 molecules)  –  which may 
become the standard of care in treating all unresectable stage III 
and IV melanomas, regardless of the BRAF mutational status, we 
here focused on molecular mechanisms involved in development 
and progression of the disease. Knowledge of such signaling 
events may contribute to better define the different subsets of 
melanoma patients as well as the molecular subtypes participat-
ing in response and resistance to targeted therapeutic approaches.
Mechanisms of Melanomagenesis
CDKN2A-Dependent Pathway
The cyclin-dependent kinase inhibitor 2A (CDKN2A) encodes 
two proteins: p16CDKN2A and p14CDKN2A (9, 10). CDKN2A is a 
recessive tumor suppressor gene and mutations in this gene 
are 7–10 times more frequent in patients with a strong family 
history of melanoma, compared to the vast majority (about 
90%) of patients with disease classified as sporadic (11). 
In physiological conditions, the system p16CDKN2A inhibits 
protein kinase cyclin-dependent kinase 4 (CDK4)/Cyclin 
D1 (CCND1), which in turn affects the cell-cycle progres-
sion depending on the RB (retinoblastoma susceptibility) 
protein (12) (Figure  1). Two major alterations reported in 
melanoma for this pathway are inactivation of p16CDKN2A and 
amplification of CCND1: the first alteration is due to genetic 
(gene mutations, chromosomal rearrangements) or epigenetic 
(methylation of promoter regions) mechanisms, while the 
second one mainly occurs in melanomas negative for muta-
tions in BRAF and NRAS genes (1, 13). In a small fraction of 
metastatic melanoma (about 15% of cases), however, CCND1 
amplification and BRAF mutations are coexisting and confer 
resistance to treatment with BRAF inhibitors (14). Similarly, 
p14CDKN2A interferes with the murine double minute 2 (MDM2) 
protein, preventing the degradation of the p53 and favoring 
its control on cell-cycle progression (15) (Figure 1). In mela-
noma, reducing levels of the p53 protein contributes to boost 
aggressiveness and refractoriness to therapy; inactivation 
of p53 can be due to mutations of p14CDKN2A or to increased 
expression of MDM2 or, alternatively, to silencing of the TP53 
gene (by epigenetic mechanisms or, to a less extent, sequence 
mutations) (12, 15).
MAPK-Dependent Pathway
The NRAS and BRAF molecules belong to the mitogen-activated 
protein kinase (MAPK) signal transduction pathway, which 
mediate the response of cells to mitotic extracellular stimuli and 
play a central role in regulating cell growth, survival, and cell pro-
liferation. The products of the RAS gene family are small proteins 
bound to the cytoplasmic membrane, with three tissue-specific 
isoforms: HRAS, KRAS, and NRAS. Among them, NRAS muta-
tions are the most detected in melanoma (2, 12, 16, 17). NRAS is 
able to activate specific cytoplasmic proteins downstream: RAF 
and phosphatidylinositol 3 kinase (PI3K) (16).
The RAF kinase family consists of three proteins (ARAF, 
BRAF, and CRAF), whose activation is depending on forma-
tion of complexes by these different isoforms (18, 19). All three 
proteins participate into the transduction of the signal within 
the MAPK pathway (12, 18). In melanocytes, BRAF induces 
the activation of MEK kinase, which in turn activates ERK, 
final effector of MAPK cascade (Figure 1). In melanoma, the 
BRAF gene is mutated in 40–60% of cases; the most prevalent 
mutation (about 90% of cases) is represented by the replace-
ment of glutamic acid with valine at codon 600 (BRAFV600E) 
(20). The BRAFV600E variant, as the remaining mutations in the 
BRAF kinase domain, induces continuous stimulation of cell 
proliferation and tumor growth through activating phospho-
rylation of ERK. However, the demonstration that BRAF is 
even mutated in common nevi (21) suggests that its oncogenic 
activation is necessary, but not sufficient, for the development 
of melanoma. In melanocytes, occurrence of BRAF mutations 
enhances the expression of p16CDKN2A (with normal levels of 
p14CDKN2A), and subsequent induction of cellular senescence 
and cell-cycle arrest mechanisms. This phenomenon appears as 
a “protective” reaction, in response to an erroneous mitogenic 
signal (22). As a confirmation of this, p16CDKN2A expression is 
reduced or absent in approximately one-third of melanomas 
with BRAFV600E mutation (22). Similarly, oncogenic activation 
of BRAF is able to promote the malignant transformation of 
melanocytes deficient in p53 (23). Therefore, BRAF cooper-
ates with members of both pathways controlled by CDKN2A 
(Figure 1).
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Pi3K-Dependent Pathway
The second pathway depending on RAS for cell growth regula-
tion is constituted by the signal transduction PTEN–PI3K–AKT 
cascade (16). Under physiological conditions, intracellular levels 
of PIP2 and PIP3 phosphoinositols are increased by activation 
of PIK3 and reduced by the activity of the phosphatase PTEN 
protein (24). High PIP3 levels sequentially activate downstream 
AKT (mainly, AKT3 in melanoma) and its substrate mTOR, 
modulating the synthesis of proteins involved in cell growth 
and survival as well as in apoptosis. In melanoma, PTEN gene is 
deleted in 30–40% of sporadic cases (with loss of the correspond-
ing protein in 5–20% of primary melanomas) and in 30–50% of 
the cell lines (2, 24). Increased expression of AKT3 is present in 
50% of dysplastic nevi, 70% of primary melanomas, and 70% of 
metastases (24). The activation of AKT: (a) promotes cell prolif-
eration through the induction and stabilization of CCND1; (b) 
inhibits apoptosis by inactivation of many pro-apoptotic proteins, 
such as BAD (BCL-2 antagonist of cell death) and MDM2 (which 
causes the degradation of p53) (1, 12) (Figure 1). In summary, 
the combined effect of PTEN inactivation and PI3K–AKT 
stimulation results in an aberrant growth of neoplastic cells, with 
acquisition of resistance to apoptosis.
Other Proliferation-Controlling effectors
Among gene products that operate downstream of the signal 
transduction BRAF–MEK–ERK pathway, the microphthalmia-
associated transcription factor (MITF) seems to play the most 
relevant role in melanoma (25). In addition to its involvement 
in skin pigmentation, MITF participates in controlling the 
proliferation and differentiation of melanocytes (26, 27). MITF 
FiGURe 1 | Major pathways involved in melanoma. Pathways associated 
with cell proliferation, survival, and differentiation are schematically presented. 
Arrows, activating signals; interrupted lines, inhibiting signals. AMPK, 
AMP-activated protein kinase; Aurk, Aurora kinase; BAD, BCL-2 antagonist of 
cell death; CDK4, cyclin-dependent kinase 4; CDKN2A, cyclin-dependent 
kinase inhibitor of kinase 2A; ERK, extracellular-related kinase; HGF, 
hepatocyte growth factor; MITF, microphthalmia-associated transcription 
factor; MEK, mitogen-activated protein kinase-extracellular-related kinase; 
PI3K, phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin homolog; 
RB, retinoblastoma protein; TERT, telomerase reverse transcriptase.
activity is complex: a low or absent expression predisposes to 
apoptosis; intermediate protein levels promote proliferation and 
cell survival; its overexpression induces cell differentiation and, 
subsequently, exerts an anti-proliferative effect (25, 27) (Figure 1; 
for further details, see below). In melanoma, constitutive acti-
vation of ERK – mainly, stimulated by oncogenic activation of 
upstream MAPK components – is associated with a marked deg-
radation of MITF (28). Therefore, the intracellular levels of MITF 
are dependent on the activation status of the BRAF gene. Low 
intracellular levels of the MITF protein have been reported in 
invasive melanomas and were associated with a worse prognosis 
and clinical progression of the disease (29).
Specific sequence variations of cKIT, a tyrosine kinase receptor 
for stem cell factor, may cause stimulation of the MAPK pathway 
through constitutive activation of the kinase domain, resulting in 
induction of cell proliferation (30). In particular, cKIT mutations 
have been reported in acral (10% of cases), mucosal (15–20% of 
cases), and chronically sun-exposed (5% of cases) melanomas 
(1, 31). In addition, cKIT amplifications or increased gene copies 
were observed at higher levels in the same series (31).
The pathogenetic scenario previously described cannot be 
considered inclusive of all molecular alterations that in recent 
years have been described in melanoma. Among these, it is 
worth mentioning the alterations of the following effectors: 
GNAQ/GNA11 genes, which encode signal transmission proteins 
activating the MAPK pathway, are quite exclusively mutated 
in uveal melanomas (32); WNT (mainly, the WNT2 isoform), 
inhibiting apoptosis in melanoma cells and acting as a potential 
marker of melanocytic malignant transformation (33); iNOS, 
which regulates the intracellular level of nitric oxide, a free 
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radical involved in the induction of apoptosis, whose increased 
production can stimulate the development and progression of 
melanoma (34); NF-kB, which is frequently activated in mela-
noma, contributing to the disease progression (12); MET, a mem-
brane receptor, activated by binding the hepatocyte growth factor 
(HGF) ligand, whose increased expression – often due to gene 
amplification – is involved in enhanced cell invasiveness (35, 36). 
Moreover, tumor microenvironment (altered distribution and 
concentration of chemokines, non-activation of cell-mediated 
immunity, induction of immune-suppressive mechanisms) may 
play an important role in the formation and maintenance of 
metastases (37, 38).
Molecular Subtypes of Melanoma
Considering the distinct molecular pathways as a unique func-
tional network (Figure 1), it becomes clear why changes attribut-
able to the influence of different genes can coexist in melanoma. 
For example, mutations in BRAF can be found associated with 
alterations in PI3K pathway, but roughly none of them coexist 
with NRAS mutations; since BRAF- and PI3K-driven cascades 
are activated downstream of NRAS, the presence of activating 
NRAS mutations makes unnecessary the occurrence of BRAF 
and PI3K activation (39). Similarly, oncogenic mutations in 
BRAF do not fully activate downstream ERK when intracellular 
mechanisms controlling senescence and/or apoptosis are active 
(12, 22). Simplifying these complex processes underlying the 
different phases of disease development and progression, it is 
possible to select distinct molecular subtypes of melanoma. The 
characterization of these subtypes becomes extremely important 
for a more correct therapeutic approach, especially after the 
introduction of targeted biological therapies into clinical practice.
 1. MAPK subtype: mutations in BRAF (targetable with specific 
BRAF-mutant inhibitors or unspecific inhibitors of the 
downstream activated MEK), which can coexist with other 
molecular alterations, providing a further stratification of 
patients:
a. activation of the PI3K–AKT–mTOR system, with 
increased levels of AKT3 expression and/or loss of 
PTEN. This subtype may benefit of treatment with 
inhibitors of PI3K, AKT, and mTOR (40);
b. impairment of the p16CDKN2A–CDK4–RB pathway, 
with inactivation of p16CDKN2A and/or amplification of 
CDK4. It may be treated with CDK4/6 inhibitors (41);
c. amplification of the MITF gene, with or without altera-
tions of the corresponding protein expression levels. 
It may benefit of treatment with inhibitors of histone 
deacetylase (HDAC), able to interfere with the expres-
sion of MITF protein (42, 43).
 2. NRAS subtype: mutations in NRAS, playing a crucial role 
in initiation and promotion of many human cancers, with 
increased levels of phospho-ERK expression, associated 
with possible activation of PI3K-AKT pathway (44). This 
subtype may benefit of treatment with inhibitors of PI3K or 
MEK (45–47). Poor effects have instead been reported using 
the specific inhibitors of farnesyl transferase (48, 49).
 3. cKIT subtype: mutations in cKIT, with or without gene 
amplification and/or increased levels of protein expression. 
For this subtype, the cKIT inhibitors are utilized in pres-
ence of specific activating mutations (in particular, variants 
K642E and L576P as well as those in exon 11), which are 
primarily responsive (50).
 4. GNAQ/GNA11 subtype: mutations in GNAQ or GNA11, 
with increased levels of expression of phospho-ERK. It may 
be treated with MEK inhibitors (47).
Molecular analyses have revealed that roughly 50% of mela-
nomas harbor BRAF mutations, whereas NRAS mutations are 
observed in 15–20% of them (44, 51). Since BRAF and NRAS 
mutations are mutually exclusive in nearly all cases (52, 53), it is 
widely recognized that about two-thirds of patients present a mela-
noma with activation of the MAPK pathway, carrying a mutated 
BRAF or NRAS gene. The BRAF mutations are especially found in 
younger individuals and in those with melanomas that originate 
on the skin not chronically exposed to the sun (54). Nearly, all 
mutations in BRAF gene are represented by a substitution of valine 
at position 600 (V600) (20). Among them, 75% of BRAF variants 
are represented by the V600E mutation, 19% by the V600K muta-
tion, the remaining 6% by V600D or V600R mutations (55).
The second-generation of RAF inhibitors, specifically targeting 
the mutated BRAF protein – such as vemurafenib, dabrafenib, and 
LGX818, potently inhibit MEK phosphorylation and cell growth 
in BRAF-mutated melanomas, being highly effective in inducing 
rapid tumor regression among melanoma patients (56–58). MEK 
is a molecular target in MAPK pathway, immediately downstream 
of BRAF. In experimental cellular models, treatment with inhibi-
tors of MEK is effective on lines mutated in either BRAF or NRAS 
(59). Allosteric inhibitors, such as selumetinib and trametinib, 
and adenosine triphosphate (ATP) non-competitive inhibitors, 
such as cobimetinib and MEK162, specific for MEK1 and MEK2 
kinases are being investigated in BRAF- or NRAS-mutated 
cutaneous melanoma as well as in metastatic uveal melanoma 
(60–62). The NRAS mutations are associated with a more aggres-
sive clinical course in melanoma patients (63); tumors carrying 
such mutations may benefit of the simultaneous inhibition of the 
MAPK and PI3K pathways (59, 64).
Resistance to Targeted Therapies in 
MAPK and NRAS Subtypes
Overall, MAPK and NRAS subtypes represent vast majority of 
melanoma cases. Tumor responses produced by the main tar-
geted inhibitors in such melanomas are largely partial and tumor 
resistance typically develops in few months as a consequence of 
the activation of alternative proliferation-inducing pathways (58, 
59). Taking in mind the complexity of the molecular mechanisms 
involved in pathogenesis of melanoma, it is mostly expected that 
inhibition of a single component in signaling pathways cannot 
yield a durable antitumor response and, conversely, that combina-
tions of drugs targeting different key effectors controlling tumor 
growth may be the solution for a more effective cancer therapy.
Moreover, several evidences indicate that molecularly het-
erogeneous cell types may coexist in primary melanomas (65–68). 
FiGURe 2 | Model of molecular effects after exposure to targeted 
drugs. Due to molecular heterogeneity of melanoma, treatment with single or 
combined target inhibitors may induce selective pressure of drug-resistant 
cells (up) or proliferative block of the different cell populations (bottom).
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Considering the various pathways involved in melanoma progres-
sion as a complex electrical circuit, it is indeed likely that different 
switches can constitutively activate different molecular processes, 
which contribute to the different characteristics of malignant 
cells (survival, independence on apoptotic stimuli, invasiveness, 
metastatic potential, etc.). When individual pathways are phar-
macologically targeted, two scenarios may arise: (a) melanoma 
cells may selectively activate alternative pathways that allow them 
to escape the growth block induced by targeted agents; or (b) the 
selective pressure may induce proliferation of subclones with 
molecular features different from those presented by vast majority 
of cell constituting the primary tumor. Recent evidence that the 
combined use of inhibitors, which simultaneously target multiple 
pathway effectors, is much more effective than treatment with sin-
gle or sequentially administered drugs (69–71) strongly supports 
the latter hypothesis, about the induction of subclonal selection 
from the heterogeneous tumors undergoing targeted therapies. In 
Figure 2, the advantage of the initial treatment with multiple target 
inhibitors is schematized. This is consistent with several indications 
coming from resistance studies in other malignancies (72–74).
To date, several mechanisms of resistance to targeted therapies 
(mostly, BRAF-mutant inhibitors) have been reported in mela-
noma (Figure 3).
intrinsic Resistance
Lack of antitumor response to commonly used BRAF inhibitors, 
vemurafenib and dabrafenib, was observed in about one-fifth of 
treated patients (75). Such an observation is strongly indicative 
for the existence of an intrinsic resistance to these drugs, which 
may be due to:
 - inactivation of PTEN tumor suppressor gene, with subse-
quent induction of downstream AKT activity (76);
 - increased intracellular levels of the cyclin D1 protein (due to 
gene amplification and/or expression enhancement), which 
overcome the inhibitory effects exerted by p16CDKN2A kinase 
and promote stimulation of the RB signaling (14). On this 
regard, cyclin D1 accumulation in melanoma cells has been 
recently reported to be partially dependent on inactivation 
of the FBXO4 gene, which encodes an enzyme regulating the 
cyclin D1 proteolysis (77);
 - silencing of the NF1 gene, which activates RAS and down-
regulates the senescence processes controlling cell prolifera-
tion (78);
 - activation of protein kinase D3 (PRKD3), enhancing the 
activity of the PI3K–AKT pathway, in response to the inhibi-
tion of the oncogenic BRAF (79).
Although apparently unrelated, all these different molecular 
alterations are able to confer resistance to BRAF or MEK inhibi-
tors in melanoma cells, through their tight interaction with the 
activity of the RAF–MEK–ERK signaling cascade. Activating 
mutations in BRAF strongly stimulates cell-cycle progression 
through constitutive stimulation of the downstream MEK–ERK 
effectors (20). Moreover, activated BRAF usually drives melano-
cytic proliferation but seems to be insufficient to promote mela-
noma growth and progression, unless alterations in additional 
cell-cycle regulating factors – such as p53 impairment, p16CDKN2A 
loss, increased levels of active AKT – coexist (2, 12).
Acquired Resistance
Two distinct schemes may be delineated for acquired resistance 
(Figure 3). The first one is based on changes progressively induced 
by BRAF inhibition within the same MAPK pathway. Reactivation 
of MAPK signaling represents the main mechanism of acquired 
resistance to BRAF inhibitors and it may be achieved through sev-
eral modifications: MEK-activating mutations, COT/MAP3K8 
kinase up-regulation (inducing a MEK–ERK activation, which is 
thus independent on upstream BRAF status), BRAFV600E splicing 
variants (unresponsive to BRAF inhibitors), BRAF-mutated gene 
amplification (rendering insufficient the BRAF inhibition levels) 
(56, 75). Both NRAS activation [through acquired mutations 
and/or functional inductions – such as its reactivation secondary 
to the reduced negative feedback by active ERK (80)] – and loss 
of NF1 have also been reported (81). Although NRAS and NF1 
act upstream of BRAF in the MAPK pathway, hyperactive NRAS 
can restore MAPK signaling in the context of BRAF inhibition via 
paradoxical activation of CRAF (82).
The second scheme includes MAPK pathway-independent 
mechanisms of acquired resistance, based on rescue of the sup-
pressed ERK activity through changes in alternative pathways 
controlling cell proliferation (Figure 3). They include activation 
of the receptor tyrosine kinases (RTKs)  –  such as the platelet-
derived growth factor receptor β (PDGFRβ) (83) or the EPHA2, a 
member of the RTK subfamily erythropoietin-producing hepato-
cellular (EPH) receptors (84, 85); activation of the HGF/MET sys-
tem (86); amplification of the CCND1 gene – with increased levels 
of the corresponding protein and subsequent activation of the 
CDK4/6-RB cascade; lack of the PTEN function (87) or enhance-
ment of the IGF-1R receptor activity (88) – with stimulation of 
the PI3K–AKT pathway; induction of the complex constituted by 
the signal transducer and activator of transcription 3 (STAT3) and 
the paired box homeotic gene 3 (PAX3) effectors – with increased 
FiGURe 3 | Main mechanisms of acquired resistance to BRAF–MeK 
inhibitors. Preexisting (pink balloons) or acquired (green balloons) 
mechanisms interfering with the antitumor activity of BRAF and/or MEK 
inhibitors. Arrows, activating signals; interrupted lines, inhibiting signals. CDK, 
cyclin-dependent kinase; COT, cancer Osaka thyroid kinase; ERK, 
extracellular-related kinase; FGFR3, fibroblast growth factor receptor 3; HGF, 
hepatocyte growth factor; IGF-1R, insulin like growth factor-1 receptor; MEK, 
mitogen-activated protein kinase-extracellular-related kinase; PAX3, paired box 
homeotic gene 3; PDGFRβ, platelet-derived growth factor receptor-beta; PI3K, 
phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin homolog RTKs, 
receptor tyrosine kinases; STAT3, signal transducer and activator of 
transcription 3.
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AKT activity (89, 90). In this scheme, BRAF inhibition does not 
produce a significant antitumor effect, since tumor growth and 
survival become independent upon RAF–MEK–ERK signaling.
RAS Activation
In about half of melanomas, presence of BRAF-mutant mono-
mers determines a constitutive activation of the downstream 
ERK effector. After BRAF inhibition, ERK signaling is switched 
off, with a reduced negative feedback on RAS. Vemurafenib and 
dabrafenib potently inhibit BRAF-mutant monomers and turn 
down the ERK activity, progressively reducing the negative 
feedback on RAS-driven signal transduction. The result is a 
progressive restoration of functional levels of active RAS-GTP, 
able to induce the generation of RAF dimers, which are resist-
ant to RAF inhibitors. The RAF homodimers (CRAF–CRAF) 
or heterodimers (BRAF-mutant–CRAF) can re-stimulate the 
MEK–ERK signaling cascade, with constitutive reactivation of 
ERK (82, 91). The RAS-driven signal transduction can be also 
stimulated by activation of the fibroblast growth factor recep-
tor 3 (FGFR3), again conferring resistance to vemurafenib in 
BRAFV600E melanoma cells (92). Increased intracellular levels of 
the RAF dimers – as consequence of the activated RAS-driven 
signal transduction  –  play also a role into the pathogenesis of 
squamous cell carcinomas, which represent a peculiar side effect 
in subsets of patients treated with BRAF inhibitors (93). RAF 
dimerization is particularly promoted by these agents in cells 
lacking BRAF mutations, leading to induction of keratinocyte 
proliferation through activation of the MAPK pathway (94–96). 
Activating mutations in NRAS (usually, affecting the codon 61 
of the gene) can be also induced by the treatment with BRAF 
inhibitors (97, 98).
Changes in BRAF
In a subset of melanomas, amplification of the BRAF-mutant 
allele  –  which has been detected at low level in untreated 
cells – may be induced in response to BRAF or MEK inhibitors, also 
contributing to resistance to these targeted drugs (99). Moreover, 
the intracellular accumulation of a splicing variant of the BRAF-
mutant mRNA has been described in a subset of BRAF-inhibitor-
resistant melanoma cells (82). In fact, such resistant cells express 
a truncated form of BRAFV600E, p61BRAFV600E, which lacks the 
region of RAS-binding domain and results constitutively activated 
through dimerization of the truncated BRAF-mutant isoforms 
(82). The final effect is a transactivation of the MEK–ERK signal 
cascade, with acquisition of resistance to BRAF inhibitors (82). 
Moreover, the vemurafenib-resistant BRAF-mutant melanomas 
may acquire dependency on the presence of the targeted drug 
for their proliferation, such that interruption in administering 
the BRAF inhibitor may lead to regression of non-lethal drug-
resistant tumors (100). On this basis, it has been postulated that a 
discontinuation in the treatment with these agents may delay the 
development of lethal drug-resistant cell clones (100).
eRK Activation via Alternative Kinases
Resistance to BRAF inhibitors may involve an alternative way of 
stimulation of the ERK signaling. Amplification of the MET recep-
tor and increased levels of its ligand, HGF, play both a role in either 
intrinsic or acquired resistance to BRAF inhibition (86, 101). In 
FiGURe 4 | Model of cell phenotype switching. Interaction between 
intracellular and microenvironmental factors may determine a continuous 
switch from a proliferative to an invasive state in melanoma cells during tumor 
progression.
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particular, activation of the HGF–MET system strongly stimulates 
the signal transduction of the downstream PI3K–AKT pathway 
(101). According to this, administration of a HGF or MET 
 inhibitor in combination with a BRAF inhibitor may prevent the 
resistance induced by using the BRAF inhibitor alone (86).
Other RTKs contribute to anti-BRAF drug resistance. The 
IGF-1R signaling also activates the MAPK pathway, participating 
into the different phases of melanocytic transformation and pro-
gression (102). Interruption of IGF-1R signaling has been shown 
to inhibit tumor growth and block metastasis formation in a wide 
variety of tumor models (88). The activated IGF-1R-dependent 
signal transduction also targets the PI3K–AKT pathway (102). 
Coupled inhibition with IGF-1R and MEK inhibitors induce 
growth arrest in BRAF inhibitor-resistant cells (88).
In a manner independent on the MAPK pathway activation, 
up-regulation of the PDGFRβ receptor may promote the expres-
sion of the transcriptional activation factors STAT3 or PAX3, 
increasing cell survival and thus reducing the effectiveness of 
BRAF or MEK inhibition (83, 103). As confirmation of this, 
inactivation of such genes may restore the block of malignant 
proliferation in vemurafenib-resistant melanoma cells (89, 90). 
Down-regulation of STAT3, by BRAF–MEK inhibitors may 
decrease the activity of anti-apoptotic protein Mcl-1 and reduce 
melanoma cell survival (104). In contrast, cells presenting up-
regulation of STAT3 – as consequence of RTK activation – may 
acquire independency on activity of the MAPK pathway for 
their proliferation and survival, with subsequent development 
of resistance to BRAF and MEK inhibitors (89, 90, 105). Finally, 
activation of RTK may be also driven by induction of the EPHA2 
signaling; in melanoma cells resistant to vemurafenib, EPHA2 
overexpression seems to contribute to cell survival and viability 
as well as to promotion of metastasis formation (84, 85).
Vast majority of data evaluating the role played by RTK-
dependent changes in acquired resistance to targeted drugs were 
produced by in vitro studies on melanoma cell lines and awaited 
to be confirmed in vivo on clinical samples.
Reactivation of MeK-eRK Pathway
BRAF or MEK inhibitors may upregulate MAP3K8 gene, giving 
an overexpression of the corresponding COT kinase, which 
in turn may stimulate the downstream MEK–ERK signaling 
cascade and lead to the development of resistance to such drugs 
(106). Alternatively, acquisition of activating mutations in either 
MAP2K1 or MAP2K2 genes (encoding MEK1 or MEK2 proteins) 
may directly reactivate the MAPK pathway (107). In particular, 
mutations in MAP2K1 gene may constitutively activate the kinase 
domain of the correspondent MEK1 protein, which therefore 
becomes either independent on activity of the upstream BRAF 
kinase either insensitive to MEK inhibitors (75).
Several alterations described for the resistance to inhibitors 
of mutated BRAF play a similar role in acquisition of resistance 
to MEK inhibitors. They include BRAF-mutant amplification, 
STAT3 up-regulation, or MAP2K1/MAP2K2 mutations (75, 105). 
The activation of the PI3K–AKT pathway also represents one of 
the main mechanisms of resistance to MEK inhibitors in BRAF-
mutant melanomas. As confirmation of this, inactivation of such 
a pathway through up-regulation of the PTEN tumor suppressor 
gene markedly increases the sensitiveness of melanoma cells to 
MEK inhibitors (108).
Resistance Through Phenotype Switching
Although other MAPK-independent mechanisms have also been 
identified, resistance still cannot be explained in up to 40% of all 
patient samples (75, 109), suggesting that additional and perhaps 
alternative systems, likely involving epigenetic events or stromal 
factors (101), remain to be identified. Recently, the occurrence of 
“phenotype switching” has been indicated as an escape mecha-
nism (Figure 4). Essentially by switching from a proliferative to 
an invasive state, melanoma cells can acquire resistance to tar-
geted therapeutics. Phenotype switching possesses a remarkable 
similarity to the epithelial-to-mesenchymal-like transition that 
has been described to occur in cancer stem cells in other tumor 
types (110) and, interestingly, the characteristics of this phenom-
enon may provide targets for new therapeutic intervention. The 
observations on this phenomenon challenged a previous model 
of melanoma progression that evokes one-way changes in gene 
expression. Expression profiling of melanoma cell lines identified 
two transcription signatures, corresponding with proliferative 
and invasive cellular phenotypes, and in vivo melanoma cells may 
switch between these two states (29). Melanoma cells with pro-
liferative signature are faster growing but less motile than those 
with invasive signature, being indeed detected most frequently 
in the peripheral margin of growing tumors. Melanoma cells 
undergo such a transcriptional signature switching in vivo, likely 
regulated by local microenvironmental conditions (29, 111).
Proliferative profile is based on up-regulation of MITF and 
other melanocytic genes (e.g., TYR, DCT, MLANA) as well as on 
involvement of additional neural crest-related factors (e.g., SOX10, 
TFAP1A, and EDNRB) (29, 111). This signature is associated with 
high rates of proliferation, low motility, and sensitivity to growth 
inhibition by TGF-beta. The invasive signature down-regulates 
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these same genes and instead up-regulates others ones (e.g., 
INHBA, COL5A1, and SERPINE1), which are involved in modi-
fying the extracellular environment (112). This second profile is 
associated with lower rates of proliferation, high motility, and 
resistance to growth inhibition by TGF-beta. In particular, MITF 
acts as a master regulator of melanocyte development, function, 
and survival, by modulating various differentiation and cell-cycle 
progression genes (28, 113) (see Figure 1). As mentioned above, 
MITF is amplified in a fraction of human melanomas (28). In 
addition to transcriptional regulation, MITF is subject to various 
post-translational modifications, which mainly include MAPK-
driven phosphorylations (113). These kinases reside within 
various important homeostatic signaling pathways and might 
therefore modulate MITF transcriptional activity in response to 
specific environmental signals. Genes targeted by MITF can be 
classified into two groups: differentiation and survival genes. The 
ability of MITF to regulate cell-cycle progression might also be 
mediated by modulation of CDK2 or the anti-apoptotic factor 
BCL2 (114). MITF can act as an anti-proliferative transcription 
factor able to induce G1 cell-cycle arrest that is dependent on 
MITF-mediated activation of the p21 cyclin-dependent kinase 
inhibitor gene (113). MITF cooperates with the retinoblastoma 
protein Rb1; combination of the MITF-mediated activation of 
p21 expression and hypo-phosphorylation of Rb1 contributes to 
cell-cycle exit and activation of a differentiation program. MITF 
amplification was prevalent in metastatic disease and correlated 
with decreased overall patient survival. Coexistence of high MITF 
expression levels and BRAF mutations is able to transform human 
melanocytes; thus, MITF can function as a melanoma oncogene 
(28, 113). Moreover, a reduction of MITF activity sensitizes 
melanoma cells to chemotherapeutic agents.
It has been evidenced that melanoma cell lines with high 
levels of MITF (MITFhigh) were sensitive to either BRAFV600E or 
MEK inhibition, whereas cells with low MITF levels (MITFlow) 
displayed intrinsic resistance against the same drugs (112). Cells 
with a so-called proliferative signature had a higher proliferation 
rate and expressed melanocyte differentiation markers, includ-
ing MITFhigh. In contrast, cell lines with an invasive signature 
displayed increased motility and migration, expressed genes 
involved in microenvironment modulation. The recent finding 
that MITFlow cells are intrinsically resistant to targeted therapy 
suggests that acquisition of an invasive phenotype results in 
resistance to MAPK inhibitors (112).
Proliferative melanoma cells could even adopt invasive char-
acteristics upon MAPK inhibition (115), indicating that targeted 
therapy could promote phenotype switching, potentially resulting 
in disease progression. This hypothesis is supported by the dis-
covery that BRAF inhibition can induce invasion and metastasis 
in vivo when tumors become resistant to therapy (115). Therefore, 
melanoma cells may use phenotype switching as a mechanism 
to evade growth arrest. On this regard, the reduced sensitivity 
to BRAF and MEK inhibition is a clear indication that invasive 
cells are less dependent on cell-regulation by MAPK activity. 
Accumulation of several genetic and/or epigenetic alterations 
may participate in reverting the phenotype and allowing survival 
in the presence of BRAF or MEK inhibition. Current  treatment 
strategies are aimed at eradicating the most proliferative cells, 
which may not necessarily be the most malignant. Future strate-
gies to identify novel drugs and active treatments will have to 
take into consideration that both proliferative and invasive 
populations should be targeted. Anyway, phenotype switching is 
a phenomenon that cannot be ignored, especially if some treat-
ments might induce switching to the invasive phenotype, thereby 
promoting metastasis formation.
Alternative Pathways in Melanoma Growth
As previously stated, cancer genomic analysis has revealed a 
marked heterogeneity within tumors (116). Although some 
common alterations (mutations in oncogenes and tumor sup-
pressor genes) exist, the pattern of alterations in many other 
genes is highly variable between individual tumors, resulting in 
considerable intra-tumor heterogeneity (117). This heterogene-
ity may represent the result of events that are positively selected 
during tumor progression and are influenced by a variety of 
factors, including the host’s genome, epigenetic changes, tumor 
microenvironment, immunologic features, and therapeutic 
interventions. Metastatic lesions, although originating from one 
or more subclones in primary tumor, continue to evolve after 
colonization of distant sites, thereby developing even greater 
levels of intra-tumor heterogeneity. Such heterogeneity raises 
a number of important issues. Clinically, intra-tumor hetero-
geneity has implications for detection of genetic events and for 
targeted therapy. Tumor sampling may have a major influence on 
whether all genetic alterations within a tumor will be detected, 
and therefore, on whether the most appropriate therapy will be 
offered to patients. Furthermore, genetic alterations that confer 
resistance to certain targeted therapies may only be present 
in specific subclones within a tumor mass, and if they are not 
detected, the patient may be subjected to inappropriate therapies.
Autophagy
The wholeness of the signaling network that protects the integrity 
of the genome during the cell cycle is a fundamental blockade 
against cell transformation. Additional protective mechanisms 
are senescence, apoptosis, and autophagy. Therefore, an extensive 
analysis of these events in cancer cells offers the opportunity 
to develop new strategies for cancer control. Autophagy is a 
fundamental process in normal and tumor cells in response to a 
variety of external stimuli (118). However, the role of autophagy is 
still controversial; it may represent a mechanism of protection or 
promotion of cell death. In addition, the significance of autophagy 
in cancer cells is also underlined by the consideration that the 
response of some types of cancer cells to chemotherapy and radio-
therapy is mediated by the activation of it, indicating a potential 
benefit an induction of autophagic cell death in cancer treatments.
Autophagy is a main lysosome-dependent process for the 
elimination of damaged or dysfunctional cellular components. 
In most cells, this self-digesting mechanism is active at a basal 
rate to maintain the balance between synthesis, degradation, 
and recycling of its constituents (119). Induction of autophagy 
leads to formation of an isolated membrane, the phagophore, 
from which it derives a double membrane cytoplasmic structure 
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called an auto phagosome (120). The vesicular structure contains 
cytoplasmic material, which fuses itself with the lysosome, 
leading to the formation of an autophago-lysosome. Finally, the 
enclosed cytoplasmic content is degraded and catabolites are 
recycled (120). Autophagy is highly regulated; it is retained at 
a basal level and induced when necessary (121). In melanocytic 
cell lineage, autophagy regulators control many cellular traf-
ficking pathways including melanin synthesis and melanosome 
formation. Autophagy has also a role in removing melanosomes 
in melanoma (121).
Multiprotein complexes are responsible for vesicle initiation, 
elongation, and fusion with the lysosome (120, 121). The initial 
step of autophagy involves ULK1/2 kinases, negatively regulated 
by mTOR. The inactivation of ULK1 in mammalian cells is suf-
ficient to inhibit autophagy induced by amino acid deprivation 
(122). On the contrary, regulators inducing autophagy include 
tumor suppressors, such as PTEN, TSC1, TSC2, and DAPK; 
stress-activated signaling molecules, such as cJun N terminal 
kinase (JNK); and those that respond to low energy, such as the 
AMPK. Inhibitors of PI3K, AKT, RAS, mTORC1, and Bcl2 are able 
to inactivate autophagy (122). At present, it has been established 
that autophagy is involved in many biological functions, such as 
cell survival, apoptosis, metabolism, development, aging, and 
immunity, contributing to the etiology of many complex diseases, 
such as cancer, neurodegenerative, and metabolic disorders (121).
Metformin and Autophagy in Melanoma
The most widely used oral antidiabetic drug metformin belongs 
to the family of biguanide drugs and it has been shown to inhibit 
the energy-sensitive AMPK target, leading to reduced protein 
synthesis and cell proliferation (123). Metformin was reported 
to act as an efficient anticancer drug in various tumors (124) as 
well as to inhibit the proliferation and invasion of melanoma 
cells (125).
Metformin inhibits mitochondrial oxidative phosphorylation, 
causing a decrease in ATP synthesis and an increase in the intra-
cellular levels of adenosine monophosphate (AMP) (126, 127). 
The reduction in cellular energy charge causes metabolic stress 
that induces the activation of AMPK. This signaling pathway 
down-regulates processes that consume energy and activates pro-
cesses that generate ATP, in keeping with the physiological role 
of AMPK as a primary regulator of cellular energy homeostasis 
(128). Activated AMPK phosphorylates downstream proteins, 
resulting in stimulation of catabolic pathways that generate ATP 
(such as glucose uptake, glycolysis, fatty acid b-oxidation, and 
mitochondrial biogenesis) and suppression of anabolic pathways, 
depending on supply of cellular ATP (such as gluconeogenesis, 
glycogen, cholesterol biosynthesis, protein, and fatty acid synthe-
sis) (123, 128). In addition to such effects on lipid and glucose 
metabolism, AMPK – through interference with the AKT–mTOR 
pathway (Figure  1)  –  is implicated in other cellular processes, 
such as cell growth and proliferation, cell-cycle regulation, apop-
tosis, and autophagy (129). Overall, metformin, as an activator of 
AMPK and an inhibitor of mTOR, may stimulate autophagy. In 
colon cancer cells and in xenograft models, metformin induces 
autophagy via AMPK (130). One study also highlighted the role 
of p53 in the induction of autophagy (131).
Therapeutic approaches using different agents able to reprogram 
energy metabolism are particularly attractive. AMPK activators 
like metformin or phentformin have been reported to inhibit the 
proliferation of transformed cells (123, 132–134). In particular, 
metformin induces cell-cycle arrest in the G0/G1 cell-cycle phase 
and a strong inhibition of cell viability by induction of autophagy 
and apoptosis in different melanoma cells independently of the 
BRAF or NRAS mutational status (132). In BRAF-mutated mela-
nomas, metformin used in combination with the BRAF inhibitor 
vemurafenib has shown a synergic antitumor effect to induce 
melanoma cell death (135). Furthermore, it has been reported 
that when another biguanide, phenformin, may cooperate with 
vemurafenib or classical chemotherapies in inhibiting the growth 
of melanoma cells (134, 136). This combined therapy could 
bypass the resistance found in response to BRAFV600E inhibitors. 
However, precautions must be taken with the use of phentformin 
in humans. Indeed, this biguanide is reported to have more toxic 
effects compared with metformin due to an unacceptable inci-
dence of severe lactic acidosis in treated patients (124).
Treatment of normal human melanocytes that express 
endogenous AMPK with metformin did not affect cell viability, 
suggesting that metformin activity is restricted to transformed 
cell lines and likely reflects a tumor specific regulation (123, 133). 
In melanoma cells, metformin can inhibit mTOR independently 
of AMPK activation and induces cell-cycle arrest, autophagy, 
and cell death. Moreover, metformin activates AMPK/p53 axis, 
to promote inhibition of melanoma metastasis, as well as induces 
down-regulation of NF-kB/STAT3 pathway, to inhibit melanoma-
initiating cells (MIC) (130, 131, 137). On this regard, MIC seem 
to be constituted by subclones in transition to proliferative 
phenotype (see above), which may be at the origin of melanoma 
metastasis (138). This could represent a further indication that 
cells within the population of tumor cells in growing melanomas 
do not display the same tumorigenic potential.
Metformin inhibits melanoma invasion and metastasis forma-
tion in mice, through dose-dependent inhibition of the expression 
of proteins involved in epithelial–mesenchymal transition (EMT) 
(139). In particular, metformin inhibits transcription factors 
required for controlling the expression of genes involved in EMT, 
such as N-cadherin, SPARC, or fibronectin (139). Again, this pro-
cess is dependent on activation of AMPK and tumor suppressor 
protein p53 (130, 131, 139). Furthermore, it is well established 
that melanoma cell invasion depends on expression of matrix 
metalloproteinases 2 and 9 (MMP-2 and MMP-9, respectively) 
(140). Both MMPs are highly expressed in melanoma cells, and 
a direct relationship between melanoma progression and MMP 
expression has been established (140). Moreover, inhibition of 
MMP activity has been previously investigated as a new therapeu-
tic strategy to control metastatic spreading. Metformin reduces 
global MMP activity and, more specifically, expression and activ-
ity of MMP-2 and MMP-9. Decreasing EMT protein expression 
and MMP inhibition may thus represent the main mechanisms 
by which metformin negatively regulate melanoma invasiveness.
Taking into account, the drastic effect of the metformin on 
melanoma cell growth, survival, invasion, and in vivo metastasis 
development, it might be worth evaluating the treatment with 
this biguanide in patients with metastatic melanoma.
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Additional Mutated Genes
Using new sequence-based approaches to comprehensively scan 
the genome for non-coding mutations with potential functional 
impact, mutations in the telomerase reverse transcriptase (TERT) 
promoter, which encodes the catalytic subunit of telomerase, were 
identified at high frequencies in cutaneous melanoma (141). TERT 
promoter mutations were found to have a UV signature and to 
lead to an increased TERT gene expression, being associated with 
poor prognosis in melanoma patients (141). Two recent reports 
described activating mutations in TERT promoter in up to 71% of 
cutaneous melanomas (142, 143). The mutations result in a two to 
fourfold increase in gene expression. Telomerase overexpression 
allows neoplastic cells to continuously proliferate without enter-
ing senescence or apoptosis by maintaining telomere length and 
avoiding chromosomal instability. Further studies are required to 
fully elucidate the role of these mutations in melanoma.
Germline mutations in BAP1 (located at 3p21) were reported 
to predispose to melanocytic tumors, including uveal and cutane-
ous melanomas (144). In addition, co-segregation with a germline 
mutation in TERT promoter has been observed in an informative 
melanoma-prone family (142), suggesting that this gene may 
also act as a rare high-penetrance melanoma susceptibility gene. 
Together, these genes account for melanoma susceptibility in a 
small proportion of melanoma-prone families.
A rare mutation (p.Ser270Asn) with founder effect in the 
protection of telomeres 1 (POT1) gene has been identified in 
melanoma-prone families (145). Carriers of this variant had 
increased telomere lengths and numbers of fragile telomeres, 
suggesting that such a variant perturbs telomere maintenance. 
POT1 is a component of the telomeric shelterin complex that 
directly binds with high specificity to single-stranded telom-
eric repeats (146). POT1 prevents inappropriate processing of 
exposed chromosome ends by DNA damage response pathways 
and regulates telomerase function, thereby having a critical role 
in maintaining telomere integrity and regulating telomere length 
(147). POT1 is a susceptibility gene for familial melanoma in other 
populations; POT1 variants were indeed found in an independent 
study of melanoma-prone families from the UK and Australia 
(148). Although the real role of POT1 in melanoma  –  as for 
TERT – needs to be fully understood, all these findings suggest 
that genes involved in telomere maintenance may contribute to 
the disease pathogenesis.
epigenetic Targets
New sequencing approaches have also unveiled a number of 
mutations in genes coding for chromatin-remodeling proteins. 
Chromatin remodeling often involves modification of histones, 
by addition or removal of covalently bound methyl, acetyl, or 
ubiquitin residues as well as by ATP-dependent remodeling of 
nucleosomes (149). One chromatin-remodeling group that is 
involved in melanoma development and progression is the SWI/
SNF complex (150). Inactivating mutations in SWI/SNF family 
member genes (ARID1A, ARID1B, ARID2, and SMARCA4) and 
in members of another chromatin-remodeling family referred to 
as the poly comb complex (EZH2, BMI1, and JARID1B/KDM5B) 
have been found altered in melanoma (107, 151–153). The role of 
chromatin-remodeling proteins in cancer is not fully understood. 
One of the most widely accepted theories is that alterations of these 
proteins result in cellular de-differentiation (149). Potentially, 
reversion of such alterations using therapeutic agents, thereby 
forcing cancer cells to regain a differentiated state, may prove to 
be clinically valuable. The role of epigenetic factors in melanoma 
pathogenesis is yet to be fully elucidated. In addition, alterations 
in DNA methylation – as hypo-methylation, leading to aberrant 
gene expression, and focal CpG island hyper methylation, which 
is generally associated with gene down-regulation – have been 
described (154). Non-coding RNAs, both short (e.g., microRNAs) 
and long, are known to be aberrantly expressed in melanoma 
and play as yet incompletely defined roles in pathogenesis (155). 
Novel compounds targeting these alterations are in development.
Epigenetic manipulation is a novel approach to cancer 
therapy that remains to be further explored in solid tumors 
(156). Epigenetic alterations may contribute to melanomagenesis 
by down-regulating tumor suppressor genes, apoptotic factors, 
and DNA repair enzymes as well as by participating in resistance 
mechanisms to therapies (157). Epigenetic drugs also seem to 
favor the endogenous antitumor immune response via several 
mechanisms (158). Furthermore, epigenetic drugs have shown 
the ability of restoring apoptotic processes that, when deregulated, 
appear crucial in the resistance to chemotherapeutics, immune 
responses, and targeted agents, such as BRAF and MEK inhibitors 
(88, 156, 158). Epigenetic mechanisms represent an important 
challenge for melanoma treatment.
Histone modifications are increasingly being involved in chro-
matin structure and gene expression regulation. In particular, 
EZH2, the catalytic subunit of the polycomb repressive complex 
2 (PRC2), is overexpressed in many different types of cancers 
including melanoma, where it represses tumor suppressor genes 
(153). EZH2 is an important driver of melanoma progression 
and EZH2 inhibitors promising therapeutic agents. Several 
epigenetic drugs including the clinically used inhibitors of DNA 
methyltransferases (DNMTi) and histone deacetylases (HDACi) 
as well as the most recently discovered inhibitors of EZH2 are 
available and may be used in combination with immune and 
targeted therapies (159).
Aurora Kinases
The aurora kinase family in mammals includes aurora kinase A 
(AurkA), B (AurkB), and C (AurkC) (160). They have many roles 
in the regulation of cell division, ensuring proper chromosome 
assembly, formation of the mitotic spindle, and cytokinesis. 
AurkA is particularly important for regulation of microtubule 
nucleation at spindle poles, whereas AurkB is essential for 
chromosome condensation, kinetochore function, cytokinesis, 
and the proper function of the spindle assembly (161). AurkA 
has long been recognized as an oncogene, due to its overexpres-
sion and amplification in several human cancers; however, it is 
unlikely to act as oncoprotein, since its over expression neither 
transforms primary cells nor leads to tumor formation (162). 
Overexpression of the aurora kinases induces aneuploidy and 
genomic instability, which have a leading role in the pathogenesis 
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of various tumors (160). Nonetheless, their powerful roles in cell-
cycle regulation and suitability for inhibition by small-molecule 
antagonists make both AurkA and AurkB promising anticancer 
therapy targets.
AurkA associates with many other key targets involved in 
tumorigenesis (163). Functionally interacting proteins include 
MYC, NF-kB, AKT1, and p53 (see Figure 1). Phosphorylating 
activity by AurkA removes inhibition of nuclear factor NF-kB, 
supporting transcription of pro-survival genes, and stimulates 
cell migration (164). Overexpression of AurkB, whose main 
partner is the survivin protein, is associated with poor outcomes 
in colon cancer, anaplastic thyroid cancer, and glioblastoma 
(165). Finally, both AurkA and AurkB associate with polo-like 
kinases and other additional partners crucial for oncogenic activ-
ity (162). For example, up-regulation of both AurkA and AurkB 
can contribute to cancerogenesis through the phosphorylation 
of p53, which accelerates MDM2-dependent degradation of 
the same p53 protein by the poly-ubiquitination-proteasome 
pathway (166). By contrast, AurkA activity is suppressed by p53 
binding, leading to an increased AurkA activation in p53-mutant 
tumors (89).
Overexpression of these kinases has been observed in several 
tumor types – including carcinomas of the colon, breast, pros-
tate, pancreas, thyroid, and head and neck – being associated 
with advanced clinical stage and poor prognosis (89). Inhibition 
of AurkA protein, which seems to be expressed at high levels 
in melanoma (163), has been shown to limit tumor growth, 
impair mitosis, and induce senescence in melanoma, suggest-
ing a potential role as therapy target (167). AurkA inhibitor 
enhanced the effect of B-RAF and MEK inhibitors on melanoma 
cell growth in a 3D human skin reconstruction model (167). 
Combined BRAF/AurkA inhibition might offer a therapeutic 
alternative to BRAF/MEK inhibition for BRAF-mutated mela-
nomas, while a combination of MEK/AurkA inhibitors could 
represent a possible option for patients without BRAF muta-
tions. Moreover, a triple drug combination including inhibitors 
of BRAF, MEK, and AurkA offered increased efficacy against 
melanoma cell growth (167); it might become a potential inno-
vative treatment strategy.
Future Perspectives
The introduction of novel techniques for genetic analyses 
may lead to a much better understanding of the mechanisms 
involved in the pathogenesis of melanoma. Assays for assessing 
the variations in DNA copy number have been introduced in 
clinical practice and are now commonly used to assist pathologic 
distinction between benign and malignant melanocytic lesions. 
A panel of molecular tests based on mutation analyses in targ-
etable effectors of the main pathways underlying development 
and progression of melanoma (particularly, components of the 
MAPK signaling cascade) – using next-generation sequencing 
(NGS) approaches  –  is being utilized for predicting purposes 
(168). Individual targeted therapies have shown promising early 
responses, but these encouraging results are mitigated by the 
rapid and frequent emergence of resistance (169). Combining 
immunotherapies and small inhibitor therapies could potentially 
alleviate the shortcomings of individual agents, leading to 
more durable responses, and, subsequently, longer survivals 
in higher numbers of patients (170). To date, in patients with 
melanomas harboring genetic alterations for which specific 
targeted therapies are not available, immunotherapies may be 
promising therapeutic options (171). Overall, considerable 
research is under way to elucidate which molecular mechanisms 
possess a clinical relevance; this could be helpful to also explore 
mechanisms of resistance and develop strategies to prevent or 
circumvent them.
Detailed genetic analysis in terms of massively parallel 
sequencing is rapidly evolving from a research tool to a potentially 
useful and widespread clinical standard for the management of 
cancer patients, particularly as the number of available targeted 
agents’ increases. The aim is to quickly translate successful 
experimental therapeutic approaches to the clinic, with patients 
receiving a personalized selection of the tested therapeutic 
modalities based on the sequencing profiles of their tumors. 
Large sequencing studies have identified several novel genetic 
alterations in melanoma (172), and additional mutations will 
inevitably be identified.
Important challenges will be to personalize and combine 
available therapeutic options based on anticipated mechanisms 
of resistance relevant to each tumor. Results from NGS-based 
analysis of multiple melanoma biopsies obtained before treat-
ment, during response to therapy, and after disease progression 
are starting to emerge, revealing important aspects of in  vivo 
resistance mechanisms. The discovery of new therapeutic com-
pounds is also awaited for a further improvement in treating 
melanomas that are resistant to existing therapies. Efforts to 
improve durability of responses will likely include double, triple, 
and even quadruple drug regimens.
Nevertheless, strategies to combine the most effective targeted 
treatments with cancer immunotherapy, which is becoming the 
standard of care in advanced melanoma, will be useful to both 
improve the clinical management and achieve much longer 
survivals among patients with such a disease.
After a very long period of dormancy in melanoma treatment, 
a new era of successful molecular-based therapeutic strategies 
has begun.
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